Form 483

InfuScience, Inc. dba Bioscrip Infusion Services Form 483, 2019-07-30

FDA issued a Form 483 to InfuScience, Inc. dba Bioscrip Infusion Services on 2019-07-30 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

InfuScience, Inc. dba Bioscrip Infusion Services · Chantilly, United States · Issued July 30, 2019

Overview

  • 6 public-safe observations are available for this inspection.
  • 1 structured CFR citation is represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

30 Jul 2019
FDCA 501(a)(2)(A)

Beta-lactam drugs, inadequate sanitation

Cited by Sena G Dissmeyer

30 Jul 2019
FDCA 501(a)(2)(A)

Cleanliness, ISO-classified areas

Cited by Sena G Dissmeyer

30 Jul 2019
FDCA 501(a)(2)(A)

Disinfectant contact time

Cited by Sena G Dissmeyer

30 Jul 2019
FDCA 501(a)(2)(A)

Disinfecting materials, aseptic processing area

Cited by Sena G Dissmeyer

30 Jul 2019
FDCA 501(a)(2)(A)

First pass air blockage, open unit with sterile product

Cited by Sena G Dissmeyer

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
FDCA 501(a)(2)(A)Cited across public-safe Form 483 observations6x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere